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A B S T R A C T
Transformation of leukemic cells is associated with delay in maturation and in apoptosis, and to altered responsive-
ness to growth factors. However, some studies have revealed that Fas (CD95/APO1) which mediates apoptotic signal and
decrease of anti-apoptotic Bcl-2 are frequently observed in acute myeloid leukemia (AML) M4/M5 leukemic cells. The aim
of the study was to compare cytomorphology and cytochemistry of bone marrow (BM) apoptotic leukemic cells to pre-
served peripheral blood (PB) leukemic cells in our patient, a 76-year-old man with AML-M5b treated at Zagreb Univer-
sity Hospital Center. BM and PB of the AL patient were analyzed after Pappenheim and cytochemical stainings, and leu-
kemic cells were classified according to FAB and WHO classification. Analysis of PB revealed leukocytosis and 80–90%
monocytic cells (46% monoblasts, 29% promonocytes and 11% monocytes). Only a few preserved monoblasts and pro-
monocytes were found in BM, together with numerous morphologically altered cells with characteristic chromatin con-
densation and pyknosis of nucleus, as well as nuclear fragmentation and formation of apoptotic bodies. Thus, cyto-
morphology of PB leukemic cells pointed to proliferation of immature monocytic cells, and cytomorphology of BM to cell
apoptosis. Cytochemistry of PB monocytic cells and BM apoptotic cells confirmed monocytic cell lineage because esterase
was strongly positive in almost all BM apoptotic leukemic cells and PB leukemic cells, and esterase was completely in-
hibited with sodium fluoride. On the basis of these findings, AML-M5b was diagnosed in our patient. There are many
possible explanations for our observation of BM leukemic cell apoptosis in a patient with AML-M5. The most reliable one
is that apoptosis was induced ex vivo after BM aspiration in course of the air drying of BM specimen before staining.
Mass BM leukemic cell apoptosis that was recorded in contrast to numerous preserved leukemic cells in PK could be
probably connected to unfavorable ratio of relatively low concentration of cytokines in relation to high leukemic cell num-
ber in BM aspirated cytologic specimen.
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Introduction
Apoptosis is a programmed cell death mechanism for
removal of unwanted cells from tissues and is an impor-
tant event in tissue development and homeostasis. There
are two main apoptotic pathways: extrinsic or death re-
ceptor pathway and intrinsic or mitochondrial pathway.
However, there is evidence now that the two pathways
are linked and that molecules in one pathway can influ-
ence those in the other. There is an additional pathway
that involves T-cell mediated cytotoxicity and perforin-
-granzyme dependent killing of the cell. Thus, the pro-
cess of apoptosis is controlled by various cell signals
which may originate either extracellularly (extrinsic in-
ducers), intracellularly (intrinsic inducers) or by inducing
granzyme pathway1,2. Extracellular signals (toxins, growth
factors, cytokines, etc.) may trigger or inhibit apopto-
sis1–4. Tumor necrosis factor (TNF) is the major extrinsic
mediator of apoptosis and binding to one of its receptors,
TNF-1 or Fas (CD95), leads to caspase activation1–4. A
cell initiates intracellular apoptotic signaling in response
to stress (heat, radiation, nutrient deprivation, hypoxia,
glucocorticoids)1–4. Apoptotic proteins induce mitochon-
drial protein SMAC (second mitochondria-derived acti-
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vator of caspases) and cytochrome c release from mito-
chondrial membrane, which are involved in the intrinsic
pathway of apoptosis. Extrinsic, intrinsic and perforin-
-dependent pathways mediate apoptosis via caspases1–5.
Apoptosis is distinguished from necrosis biochemically
and by a unique series of morphological changes, includ-
ing a decrease in cell volume and budding of cell contents
into membrane-enclosed vesicles1–6. The Bcl-2 protein
family plays a central role in the regulation of apoptosis.
To date, a total of 25 genes have been identified in the
Bcl-2 family. Some of anti-apoptotic proteins include
Bcl-2, Bcl-x, Bcl-XL, Bcl-XS, Bcl-w, Bag, and some of
pro-apoptotic proteins include Bcl-10, Bax, Bak, Bid,
Bad, Bim, Bik, and Blk. The wild type of p53 tumor sup-
pressor gene inhibits cell division and is also essential in
inducing apoptosis in cells with damaged DNA1–6. Pro-
grammed cell death appears to be an integral component
of the hematopoietic cell lineage commitment and differ-
entiation. Apoptosis also participates in the physiology of
more mature hematopoetic cells1–4. In lymphopoesis, ge-
neration of the T and B lymphocytes is dependent on rec-
ognition and the apoptotic deletion of cells with inappro-
priate specifics. Thus, T-lymphocytes undergo the selec-
tion process that uses apoptosis to eliminate cells that
recognize self antigen. Granulocyte and monocyte elimi-
nation from circulation may in part be mediated by
apoptosis1–4. Morphologic evidence of increased apoptosis
has been demonstrated in MDS, particularly in early
subtypes. In contrast, decreased apoptosis is associated
with enhanced leukemic cell survival as MDS progressed
toward AML7,8. Thus, transformation of leukemic cells is
linked to delay in maturation and in apoptosis, and to al-
tered responsiveness to growth factors7,9. In acute mo-
noblastic leukemia (M5a) and acute monocytic leukemia
(M5b), the types of acute myelod leukemia (AML), most
leukemic cells are of monocytic lineage. In M5a the ma-
jority of monocytic cells are monoblasts (80%), while in
M5b there are numerous promonocytes and monocytes
but monoblasts must comprise 20% of all nucleated
cells. AML-M5a is usually observed in young individuals
and AML-M5b is more common in adults with male:fe-
male ratio 1.8:19. In many malignant tumors and hema-
tological malignancies, induction of c-myc oncogene is
not only linked to uncontrolled cell proliferation but also
to apoptosis, depending on the presence or absence of
second survival signals such as growth factors and anti-
apoptotic factors such as Bcl-21–4,9. Indeed, some reports
pointed to the involvement of upregulation of antiapopto-
tic proteins, p21 and spliced isoform of p73 (deltaN-p73),
in pathogenesis of myelomonocytic and monocytic leu-
kemias10,11. Yet, although apoptosis in leukemic cells is a
very rare spontaneous event, there have also been re-
ports with findings that pro-apoptotic Fas (CD95/APO1),
as well as a decrease in anti-apoptotic Bcl-2, are more fre-
quently observed in M4/M5 blasts12–14.
However, to our knowledge the almost complete bone
marrow (BM) apoptosis of leukemic cells before therapy
has not been described in literature in AML patients. In
this report we present a patient with AML-M5b, bone
marrow leukemic cell apoptosis, and numerous preser-
ved immature monocytoid cells in peripheral blood (PB).
Case Report
A 76-year-old man with previously diagnosed heart
disease was admitted to Zagreb University Hospital Cen-
ter because of progressive weakness and fever. BM (FNA)
was done because of leukocytosis and thrombocytopenia.
After standard Pappenheim staining, the cytomopho-
logical analysis of BM revealed excessive number of apo-
ptotic cells (96% of all BM nucleated cells) and only sev-
eral cytomorphologically preserved cells (few monoblasts
and promonocytes and only sparse erythroblasts and
megakariocytes) (Figures 1 and 2). BM apoptotic cells
showed characteristic morphological changes of apoto-
tosis: cell shrinkage, nuclear chromatin condensation
with formation of pyknotic nuclei, convolution, invagi-
nation and fragmentation of nuclei, as well as budding of
cytoplasm (Figures 1–4). Besides apoptotic cells, apo-
ptotic bodies – small, roughly spherical or ovoid cytoplas-
mic fragments were also observed, some of which con-
tained nuclear particles (Figure 4). Quantitative analysis
of apoptotic changes was also done by cytomorphological
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Fig. 1. Bone marrow: numerous apoptotic cells with pyknotic
nuclei, one cell with early nuclear fragmentation (small arrow),
promonocytes (arrows), one monoblast (two arrows) (Pappenheim,
x1000).
Fig. 2. Bone marrow: numerous apoptotic cells, two promonocytes
(arrows), one megakaryocyte (small arrow)(Pappenheim, x1000).
analysis of Pappenheim stained BM smears and was de-
fined as apoptotic cell index, apoptotic body index and
apoptotic index (apoptotic cells and apoptotic bodies) per
1000 BM nucleated cells. In our patient, all the men-
tioned apoptotic indices were very high: apoptotic cell in-
dex was 963, apoptotic body index was 24, and apoptotic
index was 987. In PB, numerous (80–90%) monocytic
cells were found besides leukocytosis (Figure 5). Differ-
ential blood count estimated 46% monoblasts, 29% pro-
monocytes, and 11% monocytes. In almost all (about
95%) PB monocytic cells and BM apoptotic cells, al-
pha-naphthyl-acetate esterase (ANAE) was strongly pos-
itive (Figures 6 and 7) and ANAE activity was completely
inhibited with sodium fluoride (Figure 7) which is spe-
cific for monocytic cell lineage. Sudan reaction was posi-
tive in 5% of monoblasts and in 15% of promonocytes.
Blasts were negative for myelopexidase and PAS-reac-
tion. Thus, cytomorphology and cytochemistry of PB leu-
kemic cells point to proliferation of leukemic immature
monocytic cell. Cytochemistry of BM apoptotic cells con-
firmed monocytic cell lineage and AML-M5b was diag-
nosed in our patient. BM flow cytometry (FC) analysis
indicated apoptosis, i.e. the analyzed BM cell population
showed a decrease in forward light scatter which was not
paralleled by a decrease in side scatter. Moreover, specific
lineage cell antigens could not be detected in BM cells
due to unspecific binding of different lineage moAbs. By
standard cytogenetic analysis, it was not possible to iden-
tify specific cytogenetic changes, and FISH was also neg-
ative for t(9;22) and 11q23. Because of age and heart dis-
ease in our patient, reduced dose cytostatic therapy was
commenced leading to clinical improvement and reduc-
tion of leukocytosis in PB. Control BM FNA after ther-
apy was planned during continuous follow up, but the pa-
tient did not present for scheduled control examination.
Discussion
Leukocytosis and numerous monoblasts and promo-
nocytes in PB, as well as monocytic PB cell ANAE po-
sitivity (Figures 5 and 6) with complete ANAE activity
inhibition with sodium fluoride pointed in our patient to
AML-M5b9,15. However, cytological analysis of BM re-
vealed numerous morphologically altered cells and in
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Fig. 3. Bone marrow: numerous apoptotic cells. Some cells have
convoluted nuclei (arrow) and one cell showed cytoplasm bud-
ding, invagination and early fragmentation of the nucleus (two
arrows) (Pappenheim, x1000).
Fig. 4. Bone marrow: numerous apoptotic cells with pyknotic nu-
clei and budding of cytoplasm¸ cells with nuclear invagination
(two arrows) and early nuclear fragmentation (arrow); apoptotic
bodies (small arow)(Pappenheim, x1000).
Fig. 5. Peripheral blood: numerous monoblasts and promonocy-
tes (Pappenheim, x1000).
Fig. 6. Peripheral blood: numerous alpha-naphthyl-acetate este-
rase (ANAE) positive monoblasts and promonocytes (ANAE stai-
ning, x1000).
majority of BM cells it was not possible to determine
hematopoietic lineage commitment and the stage of mat-
uration. Such characteristic cytomorphological changes
firstly pointed to apoptosis (Figures 1–4). However, cy-
tomorphologic alterations of BM cells resulting in loss of
specific hematopoietic characteristics could also be cau-
sed by necrosis. Cell necrosis differs from apoptosis both
biochemically and morphologically1–6. Cell necrosis is as-
sociated with initial cell swelling, followed by plasma
membrane rupture and leakage of the cell’s content1–6.
Nuclear degeneration of necrotic cells may undergo pro-
gressive nucleus dissolution (karyolysis) which is mor-
phologically evident as nuclear swelling and loss of nu-
clear texture or progressive nuclear shrinkage or pyknosis
of nucleus1–6. Biochemically, cell necrosis is characterized
by enzymatic digestion of the cell and denaturation of
proteins1–6. On the other hand, apoptotic BM cells in our
patient showed other morphologic changes that are char-
acteristic for the process of apoptosis: cell and nucleus
shrinkage with preserved integrity of membrane; chro-
matin condensation and pyknosis of nucleus; convolu-
tion, invagination and nucleus fragmentation; cytoplasm
budding; and formation of apoptotic bodies (nuclear frag-
ments surrounded with cytoplasm which dropped from
the cell) (Figures 1–4)1–6. Biochemically, cellular orga-
nelles in early apoptotic cells are not damaged and there
is no enzymatic digestion of cytoplasm and deneatura-
tion of cytoplasmic proteins1–6. As in our patient, almost
all BM apoptotic cells were positive for the specific assay
for monocytic cell lineage, i.e. ANAE with inhibition of
ANAE activity with sodium fluoride (Figure 7), thus both
excluding cell necrosis and confirming monocytic cell lin-
eage of BM apoptotic cells9,15. One assay for determina-
tion of viable cells shares similar test principle as al-
pha-nyphtyl-acetate esterase (ANAE) cytochemistry and
employs the nonfluorescent esterase substrate, fluore-
scein diacetate. This substrate, after being taken up by
live cells, is hydrolyzed by intracellular esterases which
are ubiquitous to all types of cells. The product of the hy-
drolysis, fluorescein, ensures highly fluorescent labeling
of live and early apoptotic cells16.
Flow cytometry (FC) analysis in our patient indicated
apoptosis of BM cells, with concurrently observed de-
crease in forward light scatter as a result of cell shrink-
age, which was not paralleled by a decrease in side scat-
ter in most BM cells17,18. However, light scatter changes
are not specific to apoptosis because mechanically bro-
ken cells, isolated cell nuclei and necrotic cells also have
diminished ability to scatter light. Identification of apo-
ptosis or necrosis by light scatter therefore requires addi-
tional confirmation and should be accompanied by an-
other, more specific FC assays (flurochromes, labeling,
annexin labeling, loss of F-actin, etc.)17,18. Mostly, FC that
detect cell viability is based on the characteristic of
flurochromes to stain cells which have lost the integrity
of their plasma membrane, i.e. necrotic and late apopto-
tic cells, while early apoptotic cells are not stained17,18.
Apoptosis is accompanied by a loss of membrane phos-
pholipid asymmetry, resulting in the exposure of phoas-
phatidylserine at the cell surface, which is a principle for
the detection of apoptosis by annexin17,18. In our patient,
additional FC tests for apoptosis of BM cells were not
done since in this patient it was of primary importance to
identify cell lineage of BM leukemic cells. Cell lineage of
BM leukemic cells could not be estimated by FC analysis
with standard moAbs panel because of unspecific binding
of different moAbs on apoptotic cells. Many other differ-
ent methods can also be used to determine apoptosis:
TUNEL (TdT-mediated dUTP Nick-End Labeling) anal-
ysis, ISEL (in situ end labeling) or detection of apopto-
sis-related proteins, such as caspase-3, caspase-9, etc.1–6.
Fragmentation of the nucleus and cleavage of chromo-
somal DNA in course of apoptosis result in generation of
DNA fragments on electrophoresis. Apoptotic DNA frag-
mentation could also be detected with greater sensitivity
with PCR techniques, such as semiquantitative ligation
nucleotide PCR of blunt DNA ends1–6.
Despite high accuracy of FC analysis and other re-
fined techniques for apoptosis detection, characteristic
morphological features also enable recognition of apop-
totic cells in histological and cytological specimens19,20.
BM cells in our patient showed all morphologic changes
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Fig. 7. a) Left: numerous alpha-naphthyl-acetate esterase (ANAE) positive apoptotic cells are evident in bone marrow smear (ANAE
staining x1000); b) Right: inhibition of alpha-naphthyl-acetate esterase (ANAE) with sodium fluoride in apoptotic cells is evident in
bone marrow smear (ANAE staining x1000).
characteristic for apoptosis, and apoptotic indices linked
to these changes in apoptotic cells were extremely high.
Some of the highest apoptotic indices (AI) found in some
studies19–21 for small cell lung carcinoma (AI- 10.6), non
Hodgkin lymphoma (AI 8.8) and in acute leukemia (AI
19) were far beneath AI (987) found in the BM cell speci-
men of our patient. An interesting finding in hematologi-
cal malignancies is that indices of high proliferative cell
activity, such as Ki-67, correlate with AI19. Apoptosis is
also an integral part of normal hemopoiesis and is re-
quired for its homeostasis3,4. It has been confirmed that
BM stroma and hematopoietic growth factors (GF) are
not only required for hematopoietic stem cell (HSC) pro-
liferation and differentiation, but are also necessary for
cell survival and for prevention of apoptosis3,4. Indeed, in
normal BM almost all nucleated cells showed no evidence
of apoptotic changes and only a single apoptotic cell is a
very rare finding. Terminally differentiated cells, such as
senescent neutrophils and monocytes cannot re-enter
the cell cycle and therefore apoptotic death is a natural
fate at the end of their life spans3,4. Thus, a single or only
a few granulocytes in apoptosis could be occasionally ob-
served in PB, and they mostly present cells with pyk-
notic, completely separated ovoid fragments of nucleus.
Evidence is available that apoptosis is responsible for
the premature intramedullar death, which accounts for
peripheral cytopenias in myelodisplasia (MDS)7,8. Cer-
tain reports point to various factors involved in MDS
apoptosis, like CD40-CD40L interactions, low Bcl-2, upre-
gulated Toll-like receptor-4, B lymphocyte alterations
and overexpression of some cytokines such as TNF-re-
lated apoptosis inducing ligand -TRAIL22–26. In contrast,
decreased apoptosis is associated with enhanced leuke-
mic cell survival as MDS progresses toward-AML. Many
molecules that are expressed in leukemic cells have anti-
-apoptotic activities (altered p73, upregulated p21, Bcl-2,
Bcl-x)7,9–11. After considering this literature data, the
finding of leukocytosis in PB with monoblasts and pro-
monocytes without apoptotic morphological changes de-
spite massive BM apoptosis is highly unusual. Complex
alterations of leukemic cells that influence their prolifer-
ation, differentiation and apoptosis1–4,9 implicate many
possible explanations for such finding and some of them
are proposed as follows: 1) The cascading network of
pleitrophic genes influencing both cell-cycle events and
cell death is consistent with hypothesis that c-myc (which
can be occasionally overexpressed in AML-M5)27,28 in-
duces a two-way state in cells so that the cell chooses ei-
ther apoptosis or proliferation, depending on the pres-
ence or absence of second survival signals such as growth
factors and Bcl-21–4,14. Thus, the cells overexpressing
c-myc may proliferate relatively unchecked while nutri-
ents are available, but once these become limited, as pos-
sible in our patient due to extensive leukemic BM cell
proliferation if c-myc was overexpressed and/or Bcl-2 was
decreased, such cell may undergo apoptosis1–4,14. 2) Ac-
cording to some reports, pro-apoptotic Fas (CD95) mole-
cule (member of tumor necrosis factor – TNF family re-
ceptors including also TNFR1, TNFR2, CD30 and
CD40), which is a bad prognostic marker, is much more
frequently expressed in some AML subtypes, especially
M4 and M512,13,29. Thus, there is a possibility that blasts
in our patient with AML-M5 also have had CD95 that
could be spontaneously triggered under some circum-
stances before chemotherapy and induce apoptosis of BM
leukemic cells. Moreover, Riconi et al.30 found that espe-
cially AML-M4/M5 display a high sensitivity to Borte-
zomib-mediated apoptosis. Other studies have also indi-
cated that some molecules which could be expressed on
AML blasts (LAIR-1, CD95) could be triggered with vari-
ous agents, resulting in apoptosis of leukemic cells31–33.
3) Although stromal environment and some cytokines
(IL-1b, TNF-a, GM-CSF) provide proliferative and differ-
entiation signals, BM stromal cells were found to induce
cell death programme in the presence of some cytokines
such as INF-g, TNF, IL-6 and TG-b13,4,34. It could be ex-
plained that a difference in viability between BM and PB
leukemic cells in our patient is caused by BM stromal
cells’ ability to induce apoptosis together with BM cy-
tokines3,4,34. On the other hand, cytokines in PB (TNF,
INF-g) without stromal cell interaction and other cyto-
kines that could be found in PB (GM-CSF, G-CSF, IL-2)
delay apoptosis3,4,35–38. 4) It was also shown that PB
myeloblasts in AML had downregulated genes involved
in apoptosis with significantly better homing and engra-
fment of PB CD34+ cells in comparison to the same
immunophenotypical BM myeloblasts39. This finding al-
lowed the possibility that some differences also exist be-
tween BM and PB leukemic cells in our patient resulting
only in apoptosis of BM leukemic cells. However, all the
above numbered data are only possible explanations be-
cause additional analyses, such as CD95 or detection of
other death cell receptors, or the assay employing inhibi-
tion of apoptosis by blocking Fas/FasL interactions, or
detection of caspase-9 involved in intrinsic apoptosis
pathway, as well as cytogenetic or molecular c-myc, de-
tection were not performed1,33. Actually, there is one
more possible reliable explanation of the difference in
apoptosis between BM and PK leukemic cells that was
found in our patient. It is known that the entire process
of apoptosis occurs rapidly, with only a few hours be-
tween reception of a death signal and complete degrada-
tion of cell via apoptosis3,4. Thus, it could be considered
that apoptosis process with such high AI was induced ex
vivo after BM aspiration, because of cytokine depriva-
tion, in course of the air drying of BM specimen for two
hours before cell fixation and Pappenheim staining. Dif-
ference in leukemic cell apoptosis between BM and PK
could be probably ascribed to unfavorable ratio of high
cell number and concentration of cytokines in BM aspi-
rated cytologic specimen.
Conclusion
Cytomorphology and cytochemistry of PB leukemic
cells pointed in our patient to proliferation of immature
monocytic cells and cytomorphology of BM to cell apo-
ptosis. Cytochemistry (positive ANAE which was inhib-
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ited with sodium fluoride) of cytomorphologically chan-
ged BM cells confirmed monocytic cell lineage of apoptotic
BM cells. Such finding presents a diagnostic challenge
and provides insight in complex interactions of various
factors linked to proliferation and programmed cell death
of leukemic cells. It also allows that some molecules ex-
pressed on leukemic cells may be possible targets for new
therapeutic approaches to leukemia by inducing cell
apoptosis.
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APOPTOZA LEUKEMIJSKIH STANICA – PRIKAZ BOLESNIKA
S A @ E T A K
Transformacija leukemijskih stanica povezana je s odgodom sazrijevanja, odgodom apoptoze i promijenjenim od-
govorom na faktore rasta. Me|utim, neke studije su pokazale da se molekula Fas (CD95/APO1), koja provodi signal
apoptoze – programirane stani~ne smrti, te sni`ene vrijednosti anti-apoptoti~ke molekule Bcl-2, ~e{}e nalaze na leu-
kemijskim stanicama akutnih mijeloi~nih lekemija (AML) tipa M4 i M5. Cilj rada bio je usporediti citomorfologiju i
citokemiju apoptoti~kih leukemijskih stanica ko{tane sr`i (KS) i o~uvanih leukemijskih stanica periferne krvi (PK) u
na{eg 76 godina starog bolesnika s M5b koji je lije~en u Klini~kom bolni~kom centru Zagreb. Ko{tana sr` i periferna krv
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bolesnika analizirane su nakon standardnog bojenja po Pappenheimu i citokemijskih bojenja i akutna leukemija (AL) je
klasificirana prema kriterijima FAB (French-American-British) i SZO (Svjetska zdravstvena organizacija). Analiza PK
je pokazala leukocitozu i 80–90% monocitnih stanica (46% monoblasta, 29% promonocita i 11% monocita). U KS su
na|ene brojne morfolo{ki promijenjene stanice s karakteristi~nom kondenzacijom kromatina i piknoti~kim jezgrama,
fragmentacijom jezgri, apoptoti~ka tjele{ca, te tek nekoliko o~uvanih monoblasta i promonocita. Citomorfologija leu-
kemijskih stanica PK upu}ivala je na proliferaciju monocitnih stanica, dok je citomorfologija KS upu}ivala na apoptozu
stanica. Citokemija monocitnih stanica PK i apoptoti~kih stanica KS potvrdila je monocitnu liniju stanica jer je u go-
tovo svim leukemijskim apoptoti~nim stanicama KS i leukemijskim stanicama PK nespecifi~na esteraza bila izrazito
pozitivna i njena je aktivnost potpuno inhibirana natrijevim fluoridom. Na temelju morfologije i citokemije leukemij-
skih stanica postavljena je dijagnoza AL-M5b. Brojni poreme}aji u leukemijskim stanicama teoretski bi mogli potaknuti
apoptozu u stanicama KS u na{eg bolesnika s M5b. Do apoptoze je, me|utim, najvjerojatnije do{lo ex vivo nakon {to je
u~injena dijagnosti~ka punkcija ko{tane sr`i, dok su se citolo{ki uzorci su{ili na zraku tijekom 2 sata prije postupka
bojenja. Obja{njenje za tako velik broj apoptoti~kih leukemijskih stanica u ko{tanoj sr`i nasuprot brojnim o~uvanim
leukemijskim stanicama u PK moglo bi biti povezano s nepovoljnim odnosom relativno niske koncentracije citokina u
odnosu na izrazito velik broj leukemijskih stanica u aspiratu ko{tane sr`i.
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